Adage Capital Partners GP L.L.C. Has $76.20 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Adage Capital Partners GP L.L.C. increased its stake in Alnylam Pharmaceuticals by 203.2%, acquiring an additional 189,128 shares for a total of 282,184 shares worth approximately $76.2 million.
• Multiple institutional investors, including SVB Wealth LLC and Whipplewood Advisors LLC, have also increased their holdings in Alnylam, which is now 92.97% owned by institutional investors.
• Several analysts have raised their price targets for Alnylam Pharmaceuticals, with Barclays setting a target of $460.00 and UBS Group at $550.00, reflecting strong optimism in the company's stock performance.

Adage Capital Partners GP L.L.C. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 203.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 282,184 shares of the biopharmaceutical company's stock after purchasing an additional 189,128 shares during the quarter. Adage Capital Partners GP L.L.C. owned 0.22% of Alnylam Pharmaceuticals worth $76,195,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Comerica Bank lifted its position in shares of Alnylam Pharmaceuticals by 631.7% in the fourth quarter. Comerica Bank now owns 13,991 shares of the biopharmaceutical company's stock worth $3,292,000 after purchasing an additional 12,079 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $612,000. Captrust Financial Advisors raised its position in Alnylam Pharmaceuticals by 32.7% during the fourth quarter. Captrust Financial Advisors now owns 6,414 shares of the biopharmaceutical company's stock worth $1,509,000 after acquiring an additional 1,581 shares in the last quarter. Finally, Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 44 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded down $1.54 on Friday, hitting $452.00. The company had a trading volume of 751,495 shares, compared to its average volume of 1,065,318. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $469.81. The stock has a market cap of $59.25 billion, a price-to-earnings ratio of -183.00 and a beta of 0.32. The stock has a 50 day moving average price of $387.47 and a 200 day moving average price of $309.71. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the company earned ($0.13) earnings per share. The company's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insiders Place Their Bets

In related news, Director Michael W. Bonney sold 11,250 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares in the company, valued at approximately $7,561,800. This represents a 40.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the company's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the completion of the transaction, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock valued at $25,551,456 in the last three months. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Piper Sandler upped their price target on shares of Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $417.38.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.